Modulating LDL cholesterol and glucose in patients with type 2 diabetes mellitus: Targeting the bile acid pathway

Current Opinion in Cardiology

Volumn 23, Issue 5, 2008, Pages 502-511

  Goldfine, Allison B ^a  

^a JOSLIN DIABETES CENTER   (United States)

Author keywords

Bile acid sequestrant; Colesevelam HCl; Farnesoid X receptor; Glycemic control; Lowdensity lipoprotein cholesterol; Type 2 diabetes mellitus

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BILE ACID; CHOLIC ACID; COLESEVELAM; COLESTYRAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GLICLAZIDE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDAPAMIDE PLUS PERINDOPRIL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEGLITINIDE; METFORMIN; NICOTINIC ACID; PLACEBO; PRAVASTATIN; SIMVASTATIN; SULFONYLUREA; SULFONYLUREA DERIVATIVE; ALLYLAMINE; DRUG DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT;

ADD ON THERAPY; ATHEROSCLEROSIS; BILE ACID BLOOD LEVEL; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; DYSLIPIDEMIA; FOOD AND DRUG ADMINISTRATION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HEALTH CARE COST; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIA; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MENTAL CONCENTRATION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; RISK FACTOR; SIDE EFFECT; WEIGHT GAIN; BLOOD; DRUG EFFECT; METABOLISM; PATHOPHYSIOLOGY;

ALLYLAMINE; ANTICHOLESTEREMIC AGENTS; BILE ACIDS AND SALTS; BLOOD GLUCOSE; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERGLYCEMIA; RISK FACTORS;

EID: 58149184379     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e32830c6c37     Document Type: Review

References (73)

1. Centers for Disease Control and Prevention. National diabetes fact sheet United States. 2005. http://www.diabetes.org.
2. Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008; 31:596-615.
3. HaffnerSM, LehtoS, RonnemaaT, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:229-234.
4. Goldfine AB, Beckman JA. Life and death in Denmark: lessons about diabetes and coronary heart disease. Circulation 2008; 117:1914-1917.
5. Schramm TK, Gislason GH, Kober L, et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation 2008; 117:1945-1954.
6. Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in noninsulin dependent diabetes mellitus (UKPDS 23). BMJ 1998; 316:823-828.
7. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol. In: Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497.
8. American Diabetes Association. Standards of medical care in diabetes: 2007. Diabetes Care 2007; 30 Suppl 1:S4-S41.
9. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16:434-444.
10. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358:580-591.
11. The CDC Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 2002; 287:2542-2551.
12. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291:335-342.
13. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-853.
14. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macro-vascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321:405-412.
15. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ 1998; 317:703-713.
16. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2008; 358:2560-2572.
17. Duckworth WC. Cardiovascular outcomes by glycemic control treatment arm. Abstract presented at the 68th Annual American Diabetes Association Scientific Sessions; 6-10 June 2008; San Francisco, California.
18. Effects of Intensive Glucose Lowering in Type 2 Diabetes. N Engl J Med 2008; 358:2545-2559.
19. Stevens RJ, Kothari V, Adler AI, Stratton IM. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond) 2001; 101:671-679.
20. Betteridge DJ. Diabetic dyslipidaemia: treatment implications. J Intern Med Suppl 1994; 736:47-52.
21. Betteridge DJ. Lipids and atherogenesis in diabetes mellitus. Atherosclerosis 1996; 124 (Suppl):S43-S47.
22. Haffner SM. Management of dyslipidemia in adults with diabetes. Diabetes Care 1998; 21:160-178.
23. Rosengren A, Welin L, Tsipogianni A, Wilhelmsen L. Impact of cardiovascular riskfactors on coronary heart disease and mortality among middle aged diabetic men: a general population study. BMJ 1989; 299:1127-1131.
24. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361:2005-2016.
25. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364:937-952.
26. Ingelsson E, Schaefer EJ, Contois JH, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 2007; 298:776-785.
27. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. Circulation 1998; 98:2513-2519.
28. Pyorala K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997; 20:614-620.
29. Heart Protection Study Collaboration Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7-22.
30. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364:685-696.
31. Shepherd J, Barter P, Carmena R, et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 2006; 29:1220-1226.
32. Knopp RH, d'Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in noninsulin-dependent diabetes mellitus (ASPEN). Diabetes Care 2006; 29:1478-1485.
33. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofi-brate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001; 357:905-910.
34. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366:1849-1861.
35. Okopien B, Krysiak R, Herman ZS. Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance. J Clin Endocrinol Metab 2006; 91:1770-1778.
36. Anderlova K, Dolezalova R, Housova J, et al. Influence of PPAR-alpha agonist fenofibrate on insulin sensitivity and selected adipose tissue-derived hormones in obese women with type 2 diabetes. Physiol Res 2007; 56:579-586.
37. Bajaj M, Suraamornkul S, Hardies LJ, et al. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus. Diabetologia 2007; 50:1723-1731.
38. Jacobs MJ, Kleisli T, Pio JR, et al. Prevalence and control of dyslipidemia among persons with diabetes in the United States. Diabetes Res Clin Pract 2005; 70:263-269.
39. Insull W Jr, Toth P, Mullican W, et al. Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. Mayo Clin Proc 2001; 76:971 -982.
40. Davidson MH, Dillon MA, Gordon B, et al. Colesevelam hydrochloride (cho-lestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 1999; 159:1893-1900.
41. Hunninghake D, Insull W Jr, Toth P, et al. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis 2001; 158:407-416.
42. Florentin M, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Colesevelam hydrochloride in clinical practice: a new approach in the treatment of hypercho-lesterolaemia. Curr Med Res Opin 2008; 24:995-1009.
43. Insull W Jr. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South Med J 2006; 99:257-273.
44. The Lipid Research Clinics Coronary Primary Prevention Trial results I. Reduction in incidence of coronary heart disease. JAMA 1984; 251:351-364.
45. Garg A, Grundy SM. Cholestyramine therapy for dyslipidemia in noninsulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial. Ann Intern Med 1994; 121:416-422.
46. Zieve FJ, Kalin MF, Schwartz SL, et al. Results from the Glucose-Lowering effect Of WelChol Study (GLOWS): a randomized, double-blind pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther 2007; 29:74-83.
47. Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam HCl in diabetes patients treated with metformin: glucose and lipid effects. Arch IntMed (in press).
48. Fonseca VA, Rosenstock J, Wang AC, et al. Colesevelam HCl improves glycemic control and reduces LDL-cholesterol in patients with type 2 diabetes inadequately controlled on sulfonylurea-based therapy. Diabetes Care 2008. [Epub ahead of print]
49. Goldberg RB, Fonseca VA, Truitt KE, Jones MR. Efficacy and safety of colesevelam hydrochloride in patients with type 2 diabetes mellitus with inadequate glycemic control on insulin-based therapy. Arch Int Med (in press).
50. Bays HE, Cohen DE. Rationale and design of a prospective clinical trial program to evaluate the glucose-lowering effects of colesevelam HCl in patients with type 2 diabetes mellitus. Curr Med Res Opin 2007; 23:1673-1684.
51. Minshall ME, Hagan M, Mayo K, et al. The Cost-Effectiveness of Colesevelam HCl plus Metformin (MET) Compared with MET alone using a Validated Model from a Third-Party Payer Perspective in the USA. Abstract presented at the 68th Annual American Diabetes Association Scientific Sessions; 6-10 June 2008; San Francisco. California.
52. Kawabata Y, Ikegami H, Fujisawa T. Bile-acid binding resin ameliorates glycemic control in patients with type 2 diabetes. Diabetes 2006; 55: A120.
53. Suzuki T, Oba K, Igari Y, et al. Colestimide lowers plasma glucose levels and increases plasma glucagon-like PEPTIDE-1 (7-36) levels in patients with type 2 diabetes mellitus complicated by hypercholesterolemia. J Nippon Med Sch 2007; 74:338-343.
54. Davidson MH. The use of colesevelam hydrochloride in the treatment of dyslipidemia: a review. Expert Opin Pharmacother 2007; 8:2569-2578.
55. Staels B, Kuipers F. Bile acid sequestrants and the treatment of type 2 diabetes mellitus. Drugs 2007; 67:1383-1392.
56. Mitro N, Mak PA, Vargas L, et al. The nuclear receptor LXR is a glucose sensor. Nature 2007; 445:219-223.
57. Abrahamsson A, Gustafsson U, Ellis E, Nilsson LM, Sahlin S, Björkhem I, Einarsson C. Feedback regulation of bile acid synthesis in human liver: importance of HNF-4alpha for regulation of CYP7A1. Biochem Biophys Res Commun 2005; 330:395-399.
58. Zhang M, Chiang JY. Transcriptional regulation of the human sterol 12alpha-hydroxylase gene (CYP8B1): roles of hepatocyte nuclear factor 4alpha in mediating bile acid repression. J Biol Chem 2001; 276:41690-41699.
59. Tomlinson E, Fu L, John L, et al. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 2002; 143:1741 -1747.
60. Fu L, John LM, Adams SH, et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 2004; 145:2594-2603.
61. Hassan AS, Ravi Subbiah MT, Thiebert P. Specific changes of bile acid metabolism in spontaneously diabetic Wistar rats. Proc Soc Exp Biol Med 1980; 164:449-452.
62. Nervi FO, Gonzalez A, Valdivieso VD. Studies on cholesterol metabolism in the diabetic rat. Metabolism 1974; 23:495-503.
63. Wey HE, Yunker RL, Harris P, Subbiah MT. Effect of streptozotocin-induced diabetes in neonatal rat on bile acid pool changes in adult life: selective sensitivity in females. Biochem Med 1984; 31:167-173.
64. Thomson AB, Keelan M. Feeding rats diets containing cheno- or ursodeoxycholic acid or cholestyramine modifies intestinal uptake of glucose and lipids. Digestion 1987; 38:160-170.
65. Watanabe M, Houten SM, Mataki C, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 2006; 439:484-489.
66. Katsuma S, Hirasawa A, Tsujimoto G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun 2005; 329:386-390.
67. Andersen E, Karlaganis G, Sjovall J. Altered bile acid profiles in duodenal bile and urine in diabetic subjects. Eur J Clin Invest 1988; 18:166-172.
68. Bennion LJ, Grundy SM. Effects of diabetes mellitus on cholesterol metabolism in man. N Engl J Med 1977; 296:1365-1371.
69. Brufau G, Kuipers F, Prado K, et al. Altered Bile Salt Metabolism in Type 2 Diabetes Mellitus (T2DM). Abstract presented at the 68th Annual American Diabetes Association Scientific Sessions; 6-10 June 2008; San Francisco, California.
70. Claudel T, Staels B, Kuipers F. The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arterioscler Thromb Vasc Biol 2005; 25:2020-2030.
71. Duran-Sandoval D, Mautino G, Martin G, et al. Glucose regulates the expression of the farnesoid X receptor in liver. Diabetes 2004; 53: 890-898.
72. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281:2005-2012.
73. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005; 65:385-411.